Table 1.
Baseline characteristics of KMT2Ar adult AML patients.
| n = 205 | |
|---|---|
| Female sex | 111 (54.1%) |
| Median age in years (range) | 48.1 (18.6–86.2) |
| Age ≥ 60 years | 51 (24.9%) |
| AML type | |
| De novo AML | 148 (72.2%) |
| Secondary AML | 57 (27.8%) |
| AML after MDS | 14 (6.8%) |
| Therapy-related AML | 43 (21%) |
| Hemoglobin (g/dL) | 9.5 [Q1 = 8.3, Q3 = 11.3] |
| WBC (×109/L) | 23.1 [Q1 = 4.7, Q3 = 58] |
| (>100 × 109/L) | 21 (10.2%) |
| Platelets (×109/L) | 51.5 [Q1 = 29.8, Q3 = 107.5] |
| Bone marrow % of blasts | 83 [Q1 = 70.2, Q3 = 90] |
| Chromosomal aberrations | |
| t(9;11) | 101 (49%) |
| t(11;19) | 33 (16%) |
| t(6;11) | 24 (12%) |
| t(10;11) | 10 (5%) |
| t(11;17) | 10 (5%) |
| Other KMT2Ar | 27 (13%) |
| Additional chromosomal aberrations | 85 (41.6%) |
| Complex aberrations (≥2 apart from KMT2Ar) | 38 (19%) |
| Trisomy 8 | 37 (18%) |
| Derivative 11 | 12 (6%) |
| ELN 2022 | |
| Favorable | – |
| Intermediate | 101 (49.3%) |
| Adverse | 104 (50.7%) |
| Treatment | |
| Intensive | 195 (95%) |
| Non-intensive | 10 (5%) |
| Composite complete response | 120 (63.8%) |
| Early death | |
| 30-day mortality | 28 (13.6%) |
| 60-day mortality | 36 (17.6%) |
| Allogeneic HSCT | 88 (42.9%) |
| In CR1 | 48 (23.4%) |
| In CR2 or later | 15 (7.3%) |
| Unknown response at allo-HSCT | 25 (12.2%) |
| Median survival in years (95% CI) | 1.4 (1.1–1.7) |
AML acute myeloid leukemia, MDS myelodysplastic syndrome, WBC white blood cell, ELN European LeukemiaNet, HSCT hematopoietic stem cell transplantation, CR1 first complete remission, CR2 second complete remission, CI confidence interval.